Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 220,868
  • Shares Outstanding, K 55,286
  • Annual Sales, $ 31,560 K
  • Annual Income, $ -33,320 K
  • 60-Month Beta 1.12
  • Price/Sales 7.22
  • Price/Cash Flow N/A
  • Price/Book 8.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.11
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +8.47%
on 04/17/19
4.39 -6.61%
on 04/15/19
+0.15 (+3.80%)
since 03/22/19
3-Month
3.21 +27.73%
on 01/30/19
4.39 -6.61%
on 04/15/19
+0.63 (+18.16%)
since 01/23/19
52-Week
2.79 +46.95%
on 12/11/18
5.00 -18.00%
on 08/09/18
-0.14 (-3.30%)
since 04/23/18

Most Recent Stories

More News
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN(R) with Specialty Retail Launch and Expanded eCommerce Distribution in Canada

ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen...

CDXC : 4.11 (+2.75%)
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)

ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen(R))...

CDXC : 4.11 (+2.75%)
Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP's Sixth Annual Biohacking Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world's foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will...

CDXC : 4.11 (+2.75%)
Consolidated Research: 2019 Summary Expectations for Vishay Intertechnology, Belmond, Silicon Motion Technology, Ardmore Shipping, Northwest Pipe, and ChromaDex -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Vishay Intertechnology, Inc. (NYSE:VSH),...

ASC : 7.12 (+2.30%)
CDXC : 4.11 (+2.75%)
NWPX : 25.38 (-0.20%)
BEL : 24.99 (unch)
VSH : 19.89 (+0.66%)
SIMO : 40.12 (-4.68%)
Exactus Appoints Troy Rhonemus to Advisory Board

Exactus Inc. (OTCQB: EXDI / OTCQB: EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products, is pleased to announce the appointment of Troy Rhonemus to the Advisory...

CDXC : 4.11 (+2.75%)
EXDI : 0.9000 (unch)
ChromaDex to Present at the 31st Annual ROTH Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31 annual...

CDXC : 4.11 (+2.75%)
ChromaDex Corporation Reports 2018 Financial Results

- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million -

CDXC : 4.11 (+2.75%)
ChromaDex to Present at the 39th Annual Cowen Health Care Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39 Annual Cowen Heath Care Conference at the Boston...

CDXC : 4.11 (+2.75%)
ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31,...

CDXC : 4.11 (+2.75%)
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen)...

CDXC : 4.11 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CDXC with:

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

2nd Resistance Point 4.16
1st Resistance Point 4.08
Last Price 4.11
1st Support Level 3.94
2nd Support Level 3.88

See More

52-Week High 5.00
Fibonacci 61.8% 4.16
Last Price 4.11
Fibonacci 50% 3.89
Fibonacci 38.2% 3.63
52-Week Low 2.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar